{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:36:01Z","timestamp":1789616161899,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004488","name":"Croatian Science Foundation","doi-asserted-by":"publisher","award":["2014-09-4639"],"award-info":[{"award-number":["2014-09-4639"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.neuropharm.2018.12.018","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T16:49:58Z","timestamp":1545065398000},"page":"50-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice"],"prefix":"10.1016","volume":"148","author":[{"given":"Ana","family":"Babic Perhoc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Osmanovic Barilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Knezovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bagaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Svarc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Gr\u00fcnblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Riederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melita","family":"Salkovic-Petrisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.12.018_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nn.2709","article-title":"Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease","volume":"14","author":"D'Amelio","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.euroneuro.2010.11.009","article-title":"Insulin receptor signaling in rat hippocampus: A study in STZ (ICV) induced memory deficit model","volume":"21","author":"Agrawal","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib3","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.159.5.738","article-title":"Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies","volume":"159","author":"Alexander","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neurobiolaging.2018.01.002","article-title":"Hypermetabolism in the hippocampal formation of cognitively impaired patients indicates detrimental maladaptation","volume":"65","author":"Apostolova","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archneur.61.5.661","article-title":"Diabetes Mellitus and Risk of Alzheimer Disease and Decline in Cognitive Function","volume":"61","author":"Arvanitakis","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1242\/dmm.006239","article-title":"Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice","volume":"3","author":"Ayala","year":"2010","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00702-002-0772-x","article-title":"Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology","volume":"110","author":"Bigl","year":"2003","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.139","article-title":"Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals","volume":"4","author":"Bomba","year":"2013","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.neuropharm.2018.12.018_bib10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated A\u03b2 oligomers","volume":"124","author":"Bomfim","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/156720512799015064","article-title":"Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative Disorders","volume":"9","author":"Cai","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib12","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.bbrc.2017.11.114","article-title":"Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP\/PS1\/tau mouse model of Alzheimer's disease","volume":"495","author":"Cai","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40263-015-0301-8","article-title":"Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases","volume":"29","author":"Calsolaro","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2018.03.024","article-title":"DA5-CH, a novel GLP-1\/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP\/PS1 mouse model of Alzheimer's disease","volume":"827","author":"Cao","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s11357-011-9303-8","article-title":"Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4","volume":"34","author":"Chen","year":"2012","journal-title":"Age"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib16","article-title":"Brain Gene Expression of a Sporadic (icv-STZ Mouse) and a Familial Mouse Model (3xTg-AD Mouse) of Alzheimer's Disease","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s12035-012-8375-5","article-title":"A non-transgenic mouse model (icv-STZ Mouse) of Alzheimer's Disease: similarities to and differences from the transgenic model (3xTg-AD Mouse)","volume":"47","author":"Chen","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12264-013-1408-x","article-title":"Deregulation of brain insulin signaling in Alzheimer's disease","volume":"30","author":"Chen","year":"2014","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s12035-013-8539-y","article-title":"Intracerebroventricular streptozotocin exacerbates alzheimer-like changes of 3xTg-AD mice","volume":"49","author":"Chen","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib20","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1007\/s11064-017-2250-8","article-title":"Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP\/PS1\/Tau Triple Transgenic Mice","volume":"42","author":"Chen","year":"2017","journal-title":"Neurochem. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2018.12.018_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.9758\/cpn.2018.16.2.153","article-title":"Evaluation of acute and chronic effects of D-galactose on memory and learning in Wistar rats","volume":"16","author":"Chogtu","year":"2018","journal-title":"Clin. Psychopharmacol. Neurosci. March"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0026-0495(73)90078-4","article-title":"Galactose metabolism and its regulation","volume":"22","author":"Cohn","year":"1973","journal-title":"Metabolism"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/1536012117704557","article-title":"Brain and Brown Adipose Tissue Metabolism in Transgenic Tg2576 Mice Models of Alzheimer Disease Assessed Using 18 F-FDG PET Imaging","volume":"16","author":"Coleman","year":"2017","journal-title":"Mol. Imag."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.arr.2011.01.001","article-title":"Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease?","volume":"10","author":"Correia","year":"2011","journal-title":"Ageing Res. Rev."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2018.12.018_bib25","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1186\/1471-2202-9-S2-S16","article-title":"Hypometabolism as a therapeutic target in Alzheimer's disease","volume":"9","author":"Costantini","year":"2008","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2013.12.004","article-title":"How does brain insulin resistance develop in Alzheimer's disease?","volume":"10","author":"De Felice","year":"2014","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib27","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.euroneuro.2014.06.008","article-title":"Type 3 diabetes is sporadic Alzheimer\u05f3s disease: Mini-review","volume":"24","author":"de la Monte","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","article-title":"Brain metabolic dysfunction at the core of Alzheimer's disease","volume":"88","author":"De La Monte","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.bbr.2008.09.042","article-title":"Aged Tg2576 mice are impaired on social memory and open field habituation tests","volume":"197","author":"Deacon","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bbi.2018.03.032","article-title":"Inflammation, insulin signaling and cognitive function in aged APP\/PS1 mice","volume":"70","author":"Denver","year":"2018","journal-title":"Brain Behav. Immun."},{"issue":"133","key":"10.1016\/j.neuropharm.2018.12.018_bib31","doi-asserted-by":"crossref","DOI":"10.3791\/56685","article-title":"Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes","author":"Dinger","year":"2018","journal-title":"JoVE"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.neuroimage.2007.09.020","article-title":"Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease","volume":"39","author":"Drzezga","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","article-title":"Men and mice: Relating their ages","volume":"152","author":"Dutta","year":"2016","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.neuropharm.2018.12.018_bib34","article-title":"Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer's disease - Protocol for a controlled, randomized double-blinded trial","volume":"59","author":"Egefjord","year":"2012","journal-title":"Dan. Med. J."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00429-009-0227-3","article-title":"Presenilin transgenic mice as models of Alzheimer's disease","volume":"214","author":"Elder","year":"2010","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2013.12.012","article-title":"Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging","volume":"10","author":"Femminella","year":"2014","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib37","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/FBP.0b013e32833c8544","article-title":"Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases","volume":"21","author":"Figueiredo","year":"2010","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1096\/fasebj.10.4.8647345","article-title":"The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose","volume":"10","author":"Frey","year":"1996","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1515\/revneuro-2013-0034","article-title":"New animal models of Alzheimer's disease that display insulin desensitization in the brain","volume":"24","author":"Gao","year":"2013","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.bbadis.2013.02.018","article-title":"Early cognitive stimulation compensates for memory and pathological changes in Tg2576 mice","volume":"1832","author":"Gerenu","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/1533317510382893","article-title":"Review: disruption of the postsynaptic density in Alzheimer's disease and other neurodegenerative dementias","volume":"25","author":"Gong","year":"2010","journal-title":"Am. J. Alzheimers. Dis. Other Demen."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib43","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nrn2420","article-title":"Animal models of Alzheimer's disease and frontotemporal dementia","volume":"9","author":"G\u00f6tz","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2018.12.018_bib44","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.4103\/2230-8210.94259","article-title":"Pleiotropic effects of incretins","volume":"16","author":"Gupta","year":"2012","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158205","article-title":"Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on \u03b2-Amyloid Plaque Load in Two Transgenic APP\/PS1 Mouse Models of Alzheimer's Disease","volume":"11","author":"Hansen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib46","first-page":"497","article-title":"Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases","volume":"66","author":"H\u00f6lscher","year":"2014","journal-title":"Sheng Li Xue Bao"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib47","doi-asserted-by":"crossref","first-page":"T31","DOI":"10.1530\/JOE-13-0221","article-title":"Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases","volume":"221","author":"H\u00f6lscher","year":"2014","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib48","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jalz.2013.12.009","article-title":"The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease","volume":"10","author":"H\u00f6lscher","year":"2014","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib49","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1185\/03007995.2010.549466","article-title":"Neuroprotective properties of GLP-1: theoretical and practical applications","volume":"27","author":"Holst","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-4419-8969-7_8","article-title":"Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications","volume":"541","author":"Hoyer","year":"2004","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.274.5284.99","article-title":"Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice","volume":"274","author":"Hsiao","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib52","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/00005072-199709000-00002","article-title":"APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1","volume":"56","author":"Irizarry","year":"1997","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib53","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10821","article-title":"Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells","volume":"482","author":"Israel","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib54","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1073\/pnas.0600948103","article-title":"Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease","volume":"103","author":"Jacobsen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib55","doi-asserted-by":"crossref","first-page":"9488","DOI":"10.1038\/srep09488","article-title":"Spatial training preserves associative memory capacity with augmentation of dendrite ramification and spine generation in Tg2576 mice","volume":"5","author":"Jiang","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib56","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1007\/s12035-015-9384-y","article-title":"Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology","volume":"53","author":"Kamat","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib57","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/brain\/awh539","article-title":"Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients","volume":"128","author":"Kim","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib58","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0031-9384(02)00639-X","article-title":"Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months","volume":"75","author":"King","year":"2002","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib59","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00702-015-1394-4","article-title":"Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease","volume":"122","author":"Knezovic","year":"2015","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib60","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuropharm.2018.02.027","article-title":"Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease","volume":"135","author":"Knezovic","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.neuropharm.2013.04.008","article-title":"Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease","volume":"72","author":"Kosaraju","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib62","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jphp.12148","article-title":"Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease","volume":"65","author":"Kosaraju","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046196","article-title":"In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin","volume":"7","author":"Kraska","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib64","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006320","article-title":"Animal models of Alzheimer disease","volume":"2","author":"LaFerla","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib65","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.neuroimage.2008.12.072","article-title":"Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI)","volume":"45","author":"Langbaum","year":"2009","journal-title":"Neuroimage"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbr.2008.03.017","article-title":"Effects of the genetic background on cognitive performances of TG2576 mice","volume":"191","author":"Lassalle","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib67","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/oby.2008.267","article-title":"Amyloid Precursor Protein Expression Is Upregulated in Adipocytes in Obesity","volume":"16","author":"Lee","year":"2008","journal-title":"Obesity"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib68","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3892\/mmr.2013.1404","article-title":"Alzheimer's phenotypes induced by overexpression of human presenilin 2 mutant proteins stimulate significant changes in key factors of glucose metabolism","volume":"7","author":"Lee","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib69","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature04533","article-title":"A specific amyloid-\u03b2 protein assembly in the brain impairs memory","volume":"440","author":"Lesn\u00e9","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib70","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejphar.2011.11.005","article-title":"(Val 8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains","volume":"674","author":"Li","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib71","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","article-title":"The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-\u03b2 plaque and glial pathology in a mouse model of Alzheimer's Disease","volume":"15","author":"Long-Smith","year":"2013","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib72","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib73","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.neurobiolaging.2010.08.005","article-title":"Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease","volume":"33","author":"Luo","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib74","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer's disease: clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","article-title":"Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer's disease","volume":"76","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib76","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","article-title":"Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease","volume":"86","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib77","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2015.07.024","article-title":"Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP\/PS1 mice","volume":"293","author":"McClean","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-018-0265-5","article-title":"IPSC-derived familial Alzheimer's PSEN2N141Icholinergic neurons exhibit mutation-dependent molecular pathology corrected by insulin signaling","volume":"13","author":"Moreno","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lfs.2014.05.017","article-title":"Animal models of dementia and cognitive dysfunction","volume":"109","author":"Neha","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib80","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fnagi.2017.00345","article-title":"Insulin Resistance and Alzheimer's Disease: Bioenergetic Linkages","volume":"9","author":"Neth","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib81","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJM2003ra020003","article-title":"Alzheimer's Disease and Parkinson's Disease","volume":"348","author":"Nussbaum","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib82","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2353\/ajpath.2006.050593","article-title":"A Dynamic Relationship between Intracellular and Extracellular Pools of A\u03b2","volume":"168","author":"Oddo","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib83","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbr.2004.05.028","article-title":"Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease","volume":"156","author":"Ognibene","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib84","series-title":"Encyclopedia of Psychopharmacology","first-page":"1","article-title":"Passive Avoidance","author":"\u00d6gren","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib85","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00702-014-1323-y","article-title":"Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer's disease","volume":"122","author":"Osmanovic Barilar","year":"2015","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib86","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.nbd.2004.08.003","article-title":"Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease","volume":"17","author":"Pedersen","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib87","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.bbadis.2014.05.025","article-title":"Early alterations in energy metabolism in the hippocampus of APPswe\/PS1dE9 mouse model of Alzheimer's disease","author":"Pedr\u00f3s","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib88","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0168-9525(97)01379-6","article-title":"The fundamental importance of human galactose metabolism: lessons from genetics and biochemistry","volume":"14","author":"Petry","year":"1998","journal-title":"Trends Genet."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib89","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3233\/JAD-2010-1270","article-title":"Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates alzheimer-like changes in Tg2576 A\u03b2PP-overexpressing mice","volume":"19","author":"Plaschke","year":"2010","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib90","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.bbadis.2013.04.017","article-title":"Transgenic models of Alzheimer's disease: Better utilization of existing models through viral transgenesis","volume":"1832","author":"Platt","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib91","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00702-017-1763-2","article-title":"The diabetic brain and cognition","volume":"124","author":"Riederer","year":"2017","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib92","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00702-008-0166-9","article-title":"Metabolism of galactose in the brain and liver of rats and its conversion into glutamate and other amino acids","volume":"116","author":"Roser","year":"2009","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib93","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","article-title":"Neuroprotective and neurotrophic actions of glucagon-like peptide-1: An emerging opportunity to treat neurodegenerative and cerebrovascular disorders","volume":"166","author":"Salcedo","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib94","doi-asserted-by":"crossref","first-page":"101","DOI":"10.29245\/2572.942X\/2018\/4.1204","article-title":"Oral Galactose Provides a Different Approach to Incretin-Based Therapy of Alzheimer's Disease","volume":"3","author":"Salkovic-Petrisic","year":"2018","journal-title":"J. Neurol. Neuromedicine"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib95","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neuropharm.2013.09.002","article-title":"Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin","volume":"77","author":"Salkovic-Petrisic","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib96","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.arr.2014.09.004","article-title":"A framework to understand the variations of PSD-95 expression in brain aging and in Alzheimer's disease","volume":"18","author":"Savioz","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib97","article-title":"Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice","volume":"e52434","author":"Seibenhener","year":"2015","journal-title":"JoVE"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib98","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.nima.2006.10.143","article-title":"Raytest ClearPETTM, a new generation small animal PET scanner","volume":"571","author":"Sempere Roldan","year":"2007","journal-title":"Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectrometers, Detect. Assoc. Equip."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib99","first-page":"624","article-title":"The Laboratory Rat: Relating Its Age With Human's","author":"Sengupta","year":"2013","journal-title":"Int. J. Prev. Med."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbr.2017.03.032","article-title":"A novel dual GLP-1\/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model","volume":"327","author":"Shi","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib101","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.neurobiolaging.2010.12.002","article-title":"Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents","volume":"33","author":"Shonesy","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib102","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exger.2017.10.029","article-title":"Role of D-galactose-induced brain aging and its potential used for therapeutic interventions","volume":"101","author":"Shwe","year":"2018","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib103","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ejphar.2015.09.024","article-title":"Exenatide reduces TNF-\u03b1 expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats","volume":"765","author":"Solmaz","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib104","doi-asserted-by":"crossref","first-page":"7278","DOI":"10.1523\/JNEUROSCI.1879-05.2005","article-title":"Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy","volume":"25","author":"Spires","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172260","article-title":"Of the milk sugars, galactose, but not prebiotic galacto-oligosaccharide, improves insulin sensitivity in male Sprague-Dawley rats","volume":"12","author":"Stahel","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib106","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.brainres.2017.10.012","article-title":"Neuroprotective effects of a triple GLP-1\/GIP\/glucagon receptor agonist in the APP\/PS1 transgenic mouse model of Alzheimer's disease","volume":"1678","author":"Tai","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib107","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.brainres.2017.10.012","article-title":"Neuroprotective effects of a triple GLP-1\/GIP\/glucagon receptor agonist in the APP\/PS1 transgenic mouse model of Alzheimer's disease","volume":"1678","author":"Tai","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib108","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0002-9440(10)64544-0","article-title":"Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss","volume":"157","author":"Takeuchi","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib109","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/nmt.13.73","article-title":"Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs","volume":"4","author":"Talbot","year":"2014","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib110","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jalz.2013.12.007","article-title":"The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease","volume":"10","author":"Talbot","year":"2014","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib111","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib112","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/oby.21494","article-title":"Effects of glucose and insulin on secretion of amyloid-\u03b2 by human adipose tissue cells","volume":"24","author":"Tharp","year":"2016","journal-title":"Obesity"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib113","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1096\/fj.14-268482","article-title":"Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease","volume":"29","author":"Vandal","year":"2015","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib114","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nprot.2006.116","article-title":"Morris water maze: procedures for assessing spatial and related forms of learning and memory","volume":"1","author":"Vorhees","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib115","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nprot.2007.44","article-title":"The use of the elevated plus maze as an assay of anxiety-related behavior in rodents","volume":"2","author":"Walf","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib116","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3758\/BF03335949","article-title":"Passive avoidance learning in rats, mice, gerbils, and hamsters","volume":"22","author":"Walters","year":"1971","journal-title":"Psychonomic Sci."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib117","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1523\/JNEUROSCI.22-05-01858.2002","article-title":"The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease","volume":"22","author":"Westerman","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.018_bib118","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2337\/db14-0287","article-title":"Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease","volume":"63","author":"Yarchoan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2018.12.018_bib119","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.1038\/s41598-018-24710-7","article-title":"Maternal imprinting on cognition markers of wild type and transgenic Alzheimer's disease model mice","volume":"8","author":"Zamarbide","year":"2018","journal-title":"Sci. Rep."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818305926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818305926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T15:38:58Z","timestamp":1662651538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818305926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":119,"alternative-id":["S0028390818305926"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.12.018","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}